Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has announced the sale of a portfolio of non-core products to Almirall for a cash consideration of $213 million.
Subscribe to our email newsletter
The portfolio includes the dermatology products, Solaraze (3% gel diclofenac sodium) and Vaniqa (eflornithine hydrochloride), and six other non-promoted products across a range of indications, which are principally sold by Shire in the UK, France, Germany, Italy, Spain and Ireland.
Shire said that the divested products were no longer core to its strategy of building market leading positions in specialty markets through the development and commercialization of competitive global products with strong intellectual property protection.
Matthew Emmens, chief executive of Shire plc, said: “Our strategic focus is clear and our emphasis in the international markets is on developing competitive positions for our global products that meet the needs of the specialist physicians and their patients, in our chosen areas of expertise. Almirall is well positioned to ensure future development and investment in the products we are divesting, which are no longer core to our strategy.”